Text Size

Comparison of Analgesic Efficacy of Fentanyl, Sufentanil and Butorphanol After Remifentanil Anesthesia (CARAN)

This study has been completed.
Sponsor:
Information provided by:
Nanjing Medical University
ClinicalTrials.gov Identifier:
NCT00738192
First received: August 18, 2008
Last updated: March 10, 2009
Last verified: March 2009
History of Changes
  Purpose

Fast awakening from anesthesia is one of the major characteristics of remifentanil-associated anesthetic induction and maintenance, whereas corresponding pain during awakening influences patient's rehabilitation strongly. In addition, such early postoperative pain results in significant stress responses, which displays as further release of stress hormones such as cortisol and β-endorphin as well. How to prevent such acute pain resulting from remifentanil's fast metabolism endows clinical significance. This study is designed to compare the analgesic efficacy of fentanyl, sufentanil and butorphanol delivered after gynecological laparoscopic surgeries that underwent remifentanil induction and maintenance, and investigate corresponding influence on the levels of blood cortisol and β-endorphin.


Condition Intervention Phase
Postoperative Pain
 Drug: Fentanyl citrate
Drug: Sufentanil citrate
Drug: Butorphanol tartrate
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Comparison of Analgesic Efficacy of Fentanyl, Sufentanil and Butorphanol After Remifentanil Anesthesia in Gynecological Laparoscopic Surgeries

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Nanjing Medical University:

Primary Outcome Measures:
  • VAS ratings of pain [ Time Frame: 0 min after awake from anesthesia; 5,10,15,20 and 30min after awake from anesthesia ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Hemodynamics of patients [ Time Frame: 30min before operation; every 10min during operation; 5,10,15,20,30 and 60min after operation ] [ Designated as safety issue: Yes ]
  • Sedative ratings with VAS system [ Time Frame: 0,5,10,15,25,45 and 60min after awake from anesthesia ] [ Designated as safety issue: Yes ]
  • Overall VAS satisfaction ratings [ Time Frame: 1 h after operation ] [ Designated as safety issue: Yes ]
  • Blood cortisol and β-endorphin levels [ Time Frame: 0, 10min before the end of surgeries, 10min, 1h and 6h after operation ] [ Designated as safety issue: No ]
  • Side effects [ Time Frame: 1 h after operation ] [ Designated as safety issue: Yes ]

Enrollment: 150
Study Start Date: July 2008
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Fentanyl delivered for controlling awaking pain
 Drug: Fentanyl citrate
Fentanyl 0.5 μg/kg delivered intravenously immediate at the end of remifentanil pump finished
Other Name: Fentanil
Active Comparator: 2
Sufentanil delivered for controlling awaking pain
 Drug: Sufentanil citrate
Sufentanil 0.05 μg/kg delivered intravenously immediate at the end of remifentanil pump finished
Other Name: Sufenil
Active Comparator: 3
Butorphanol delivered for controlling awaking pain
 Drug: Butorphanol tartrate
Butorphanol 0.01 mg/kg delivered intravenously immediate at the end of remifentanil pump finished
Other Name: Nuoyung

  Eligibility

Ages Eligible for Study:   19 Years to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. ASA physical status I-II
  2. Chinese
  3. 19-45yr
  4. Selective laparoscopic surgeries

Exclusion Criteria:

  1. Allergy to opioids, a history of the use of centrally-acting drugs of any sort, chronic pain and psychiatric diseases records
  2. Participants younger than 18 years, older than 45 years or pregnancy was eliminated
  3. Due to the significant changes in vital signs might affect cognition of pain and that of sensation, over 20% variation of these records from the baselines or below 92% of SpO2 under 20-40% nasal tube oxygen at any time should be excluded from the study
  4. Those who were not willing to or could not finish the whole study at any time
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00738192

Locations
China, Jiangsu
Nanjing Maternal and Child Health Care Hospital
Nanjing, Jiangsu, China, 210004
Sponsors and Collaborators
Nanjing Medical University
Investigators
Study Chair: XiaoFeng Shen, MD Nanjing Medical University
  More Information

No publications provided

Responsible Party: XiaoFeng Shen, Nanjing Medical University
ClinicalTrials.gov Identifier: NCT00738192     History of Changes
Other Study ID Numbers: NMU-FY2008-311, NJFY0807311M
Study First Received: August 18, 2008
Last Updated: March 10, 2009
Health Authority: China: Ethics Committee

Keywords provided by Nanjing Medical University:
Postoperative analgesia
Opioids
Laparoscopic surgery

Additional relevant MeSH terms:
Pain, Postoperative
Postoperative Complications
Pathologic Processes
Pain
Signs and Symptoms
Analgesics
Butorphanol
Fentanyl
Remifentanil
Sufentanil
Anesthetics
Citric Acid
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
 Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Central Nervous System Depressants
Analgesics, Opioid
Antitussive Agents
Respiratory System Agents
Narcotic Antagonists
Narcotics
Anticoagulants
Hematologic Agents
Chelating Agents
Molecular Mechanisms of Pharmacological Action
Adjuvants, Anesthesia
Anesthetics, Intravenous

ClinicalTrials.gov processed this record on May 22, 2013